Zoetis Inc. reports developments as a global animal health company serving veterinarians, livestock producers and pet owners. Its updates center on medicines, vaccines, diagnostics, biopharmaceuticals and digital solutions for companion animals and livestock, organized commercially through U.S. and International segments.
Recurring news includes quarterly results and guidance, dividend declarations, investor conference presentations, pipeline and product-regulatory updates, and portfolio activity tied to animal health innovation. Company materials also describe R&D work across areas such as chronic kidney disease, oncology, cardiology, anxiety and obesity, as well as approved long-acting osteoarthritis pain products Lenivia and Portela.
Zoetis (NYSE:ZTS) reported Q1 2026 revenue of $2.3B (+3% reported, flat organic) and net income of $601M ($1.42 diluted). Adjusted net income was $646M ($1.53 adjusted diluted EPS). The company revised 2026 guidance to $9.68B–$9.96B revenue and adjusted EPS $6.85–$7.00. U.S. revenue fell 8%; International grew 17% reported. Zoetis agreed to acquire Neogen’s animal genomics business and completed a fiscal year alignment effective Jan 1, 2026.
Zoetis (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. ET on Thursday, May 7, 2026 to review first quarter 2026 financial results. CEO Kristin Peck and EVP & CFO Wetteny Joseph will present and take questions from financial analysts.
Investors may access the live webcast and slides via the company investor website; pre-registration opens today and a replay will be posted on May 7, 2026.
Zoetis (NYSE:ZTS) announced that CEO Kristin Peck will participate in a fireside chat at the KeyBanc Capital Markets Healthcare Forum on March 17, 2026 at 10:30 a.m. ET. Interested parties can listen via a live audio webcast with a replay available on the company website.
Zoetis (NYSE:ZTS) announced that Wetteny Joseph, Executive Vice President and Chief Financial Officer, will appear in fireside chats at two investor conferences on March 9–10, 2026.
The events are the Leerink Global Healthcare Conference on March 9 at 3:00 p.m. ET and the Barclays 28th Annual Global Healthcare Conference on March 10 at 9:30 a.m. ET; live audio webcasts and replays will be available via the company's investor website.
Zoetis (NYSE: ZTS) will acquire Neogen's animal genomics business for $160 million, enhancing its Precision Animal Health capabilities.
The purchase adds five global laboratories, expanded genotyping and sequencing platforms, and software tools; Zoetis expects to close in the second half of 2026, subject to regulatory approvals and customary closing conditions.
Zoetis (NYSE:ZTS) will participate in the Bank of America Securities 2026 Animal Health Summit on Thursday, February 26, 2026 at 1:15 p.m. ET.
Wetteny Joseph, executive vice president and chief financial officer, will represent the company. According to Zoetis, a live audio webcast will be available at the company investor events page and a replay will follow after the event.
Zoetis (NYSE: ZTS) reported Q4 2025 revenue of $2.4B (+3% reported, +4% organic) and Q4 net income of $603M ($1.37 diluted). Full-year 2025 revenue was $9.5B (+2% reported, +6% organic) with net income $2.7B ($6.02 diluted).
Adjusted 2025 EPS: $6.41. 2026 guidance: revenue $9.825–$10.025B, adjusted EPS $7.00–$7.10, and expected 3–5% organic revenue growth.
Zoetis (NYSE:ZTS) declared a second-quarter 2026 cash dividend of $0.53 per share. The dividend will be paid on June 2, 2026 to holders of record at the close of business on April 20, 2026.
Zoetis (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. ET on Thursday, February 12, 2026 to review fourth-quarter and full-year 2025 financial results.
CEO Kristin Peck and EVP & CFO Wetteny Joseph will present and take questions from financial analysts. Investors and the public can access the live webcast at http://investor.zoetis.com/events-presentations. Pre-registration opens today, and a replay will be available on February 12, 2026.
Zoetis (NYSE:ZTS) will participate in the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026. Kristin Peck, CEO, and Wetteny Joseph, EVP and CFO, will present and answer analyst questions at 10:30 a.m. PT. Investors can listen to a live audio webcast at the company's investor site and access a replay on the Zoetis website after the event.